ERCC1 Targeted Trial

NCT00801736 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

648

Enrollment

OTHER

Sponsor class

Stopped The antibody used did not appear prognostic/predictive based on interim results.

Conditions

Lung Cancer

Interventions

DRUG: Cisplatin, Paclitaxel

Sponsor

University College, London

Collaborators

[object Object]
[object Object]